Sponsor

Merck Sharp & Dohme LLC

Clinical research sponsor

How to interpret these research links

Connected source records

The exact organization name Merck Sharp & Dohme LLC appears in 1,573 distinct published trial records. The links retain registry-reported sponsor and collaborator roles; differently spelled legal entities are not automatically merged. Recruiting status describes the current published registry snapshot, not an independently verified availability guarantee.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Published trials1,573
Recruiting shown48
Roles2
SourceClinicalTrials.gov
Advertisement

Clinical trials

60 shown
A Clinical Trial of MK-8748 Compared to Aflibercept in Participants With Diabetic Macular Edema (MK-8748-005)NCT07705607 · lead sponsor · 2026-09-25
RECRUITING
A Study of Sotatercept (MK-7962) in Japanese Children With Pulmonary Arterial Hypertension (PAH) (MK-7962-032)NCT07646860 · lead sponsor · 2026-09-17
RECRUITING
A Clinical Trial of MK-8748 Compared to Aflibercept in Participants With Diabetic Macular Edema (MK-8748-004)NCT07705555 · lead sponsor · 2026-08-27
RECRUITING
A Clinical Trial of Calderasib (MK-1084) and Durvalumab in People With Non-Small Cell Lung Cancer (MK-1084-015/KANDLELIT-015)NCT07554339 · lead sponsor · 2026-06-18
RECRUITING
A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014)NCT07513376 · lead sponsor · 2026-05-04
RECRUITING
A Clinical Study of MK-1084 With Other Treatments for Non-small Cell Lung Cancer (MK-3475-01F)NCT07286149 · lead sponsor · 2026-04-30
RECRUITING
MK-3475A±Calderasib (MK-1084) in Completely Resected Stage IIA-IIIB (N2) KRAS G12Cm NSCLC (MK-1084-013)NCT07431827 · lead sponsor · 2026-03-18
RECRUITING
A Clinical Study of MK-1045 in People With Lupus or Rheumatoid Arthritis (MK-1045-004)NCT07363590 · lead sponsor · 2026-02-19
RECRUITING
A Clinical Study of Gocatamig (MK-6070) and Infinatamab Deruxtecan (MK-2400) in People With Small Cell Lung Cancer (MK-6070-003)NCT07227597 · lead sponsor · 2026-01-29
RECRUITING
A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)NCT07216703 · lead sponsor · 2026-01-19
RECRUITING
KEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants With Non-Small Cell Lung Cancer (NSCLC) With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) G12C Mutations (MK-3475-01J/KEYMAKER-U01J)NCT07252739 · lead sponsor · 2025-12-19
RECRUITING
A Clinical Study of Islatravir and Ulonivirine for People With HIV-1 Who Have Not Been Treated Before (MK-8591B-062)NCT07266831 · lead sponsor · 2025-12-18
RECRUITING
A Study of Intismeran Autogene (V940)/Placebo + Pembrolizumab and Chemotherapy in Metastatic Squamous Non-Small Cell Lung Cancer (V940-013)NCT07221474 · lead sponsor · 2025-12-12
RECRUITING
A Study of MK-8527 to Prevent Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8527-010)NCT07071623 · lead sponsor · 2025-11-10
RECRUITING
A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)NCT07190248 · lead sponsor · 2025-10-08
RECRUITING
A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)NCT07060807 · lead sponsor · 2025-07-21
RECRUITING
A Clinical Study of MK-2214 in People With Early Alzheimer's Disease (MK-2214-004)NCT07033494 · lead sponsor · 2025-07-16
RECRUITING
A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02)NCT06863272 · lead sponsor · 2025-07-03
RECRUITING
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)NCT06966700 · lead sponsor · 2025-06-30
RECRUITING
A Clinical Study of Intismeran Autogene (V940) and Pembrolizumab (MK-3475) in People With Melanoma (V940-012/INTerpath-012)NCT06961006 · lead sponsor · 2025-05-29
RECRUITING
Substudy 01I: A Study of Investigational Agents in Participants With Previously Treated Stage IV Squamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01I/KEYMAKER-U01I)NCT06780098 · lead sponsor · 2025-05-28
RECRUITING
A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)NCT06952504 · lead sponsor · 2025-05-22
RECRUITING
A Study of Investigational Agents in Participants With Previously Treated Stage IV Nonsquamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01H/KEYMAKER-U01)NCT06780085 · lead sponsor · 2025-05-13
RECRUITING
A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)NCT06925737 · lead sponsor · 2025-05-13
RECRUITING
A Study of Pembrolizumab With or Without Chemotherapy in Combination With Additional Treatments for Advanced Non-Small Cell Lung Cancer (NSCLC) (MK-3475-01G/KEYMAKER U01)NCT06731907 · lead sponsor · 2025-03-30
RECRUITING
Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)NCT06797635 · lead sponsor · 2025-03-20
RECRUITING
A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)NCT06841354 · lead sponsor · 2025-03-16
RECRUITING
A Study to Evaluate the Safety and Efficacy of Gocatamig (MK-6070) and Ifinatamab Deruxtecan (I-DXd) in Participants With Relapsed/Refractory Extensive-Stage Small Cell Lung Cancer (MK-6070-002)NCT06780137 · lead sponsor · 2025-02-27
RECRUITING
Study of Patritumab Deruxtecan With Other Anticancer Agents in Participants With HER2 Positive Breast Cancer That Has Spread and Cannot Be Surgically Removed (MK-1022-009)NCT06686394 · lead sponsor · 2025-02-26
RECRUITING
A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)NCT06623422 · lead sponsor · 2024-10-21
RECRUITING
Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)NCT06469944 · lead sponsor · 2024-09-20
RECRUITING
Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06)NCT06445972 · lead sponsor · 2024-08-07
RECRUITING
Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)NCT06393374 · lead sponsor · 2024-06-24
RECRUITING
Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]NCT06422143 · lead sponsor · 2024-06-10
RECRUITING
A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)NCT06345729 · lead sponsor · 2024-05-24
RECRUITING
Substudy 01A: Safety and Efficacy of Opevesostat (MK-5684)-Based Treatment Combinations or Opevesostat Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-01A)NCT06353386 · lead sponsor · 2024-05-20
RECRUITING
A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)NCT06312176 · lead sponsor · 2024-04-14
RECRUITING
A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)NCT06312137 · lead sponsor · 2024-04-03
RECRUITING
Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)NCT06136624 · lead sponsor · 2023-12-31
RECRUITING
A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)NCT06136650 · lead sponsor · 2023-12-18
RECRUITING
Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)NCT06170788 · lead sponsor · 2023-12-15
RECRUITING
Efficacy, Safety, and Pharmacokinetics of Vericiguat in Pediatric Participants With Heart Failure Due to Left Ventricular Systolic Dysfunction (MK-1242-036)NCT05714085 · lead sponsor · 2023-05-31
RECRUITING
A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B)NCT05319730 · lead sponsor · 2023-05-16
RECRUITING
Study to Evaluate Sotatercept (MK-7962) in Children With Pulmonary Arterial Hypertension (PAH) (MK-7962-008)NCT05587712 · lead sponsor · 2023-01-19
RECRUITING
A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (MK-7962-038)NCT07218029 · lead sponsor · 2021-05-12
RECRUITING
Doravirine (DOR) in Human Immunodeficiency Virus (HIV)-Infected Children Aged 4 Weeks to <12 Years and <45 kg (MK-1439-066)NCT04375800 · lead sponsor · 2021-02-03
RECRUITING
KEYMAKER-U01 Substudy 01A: Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Chemotherapy When Used With Investigational Agents in Treatment-naïve Participants With Stage IV Non-small Cell Lung Cancer (NSCLC) (MK-3475-01A/KEYMAKER-U01A)NCT04165070 · lead sponsor · 2019-12-19
RECRUITING
KEYMAKER-U01 Umbrella Master Study: Studies of Investigational Agents With Either Pembrolizumab (MK-3475) Alone or With Pembrolizumab PLUS Chemotherapy in Participants With Non-small Cell Lung Cancer (NSCLC) (MK-3475-U01/KEYMAKER-U01)NCT04165798 · lead sponsor · 2019-12-19
RECRUITING
DOR/ISL in Pediatric Participants With HIV-1, <18 Years of Age and ≥ 35 kgNCT07862569 · lead sponsor · 2026-12-23
NOT_YET_RECRUITING
A Clinical Study of Sotatercept (MK-7962) in People With Combined Postcapillary and Precapillary Pulmonary Hypertension and Heart Failure With Preserved Ejection Fraction (MK-7962-041)NCT07839585 · lead sponsor · 2026-11-26
NOT_YET_RECRUITING
A Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (PAH) in India (MK-7962-037)NCT07600723 · lead sponsor · 2026-11-04
NOT_YET_RECRUITING
A Clinical Study of Alimatravir (MK-8527) in Transgender (Trans) and Gender Diverse Individuals on Gender-affirming Hormone Therapy and at Low Likelihood of Human Immunodeficiency Virus (HIV)-1 Exposure (MK-8527-018)NCT07850609 · lead sponsor · 2026-10-29
NOT_YET_RECRUITING
A Clinical Trial of MK-8527 and Rifampin in Adult Participants With Latent Tuberculosis Infection (MK-8527-019)NCT07600775 · lead sponsor · 2026-09-01
NOT_YET_RECRUITING
A Clinical Trial of Multiple Formulations of MK-4082 in Healthy Overweight and Obese Participants (MK-4082-007)NCT07748351 · lead sponsor · 2026-08-25
ACTIVE_NOT_RECRUITING
A Clinical Study of MK-4082 in Healthy Overweight Participants (MK-4082-002)NCT07388667 · lead sponsor · 2026-03-04
COMPLETED
A Clinical Trial of MK-1403 in Participants With Type 2 Diabetes Mellitus (MK-1403-006)NCT07242469 · lead sponsor · 2025-12-22
COMPLETED
A Clinical Study of Tulisokibart (MK-7240) to Treat Rheumatoid Arthritis (RA) (MK-7240-014)NCT07176390 · lead sponsor · 2025-10-08
ACTIVE_NOT_RECRUITING
Multiple Dose Study of MK-2828 in Participants With Type 2 Diabetes (MK-2828-003)NCT07089784 · lead sponsor · 2025-09-22
COMPLETED
A Clinical Study of MK-8527 to Prevent Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8527-011)NCT07044297 · lead sponsor · 2025-07-31
ACTIVE_NOT_RECRUITING
MK-4646 Multiple Dose Trial in Participants With Human Immunodeficiency Virus Type 1 (HIV-1) (MK-4646-003)NCT07042945 · lead sponsor · 2025-07-09
COMPLETED

Drugs studied in this sponsor's trials

278 mapped RxNorm concepts

These drug records are connected through ClinicalTrials.gov studies listing Merck Sharp & Dohme LLC as a sponsor, collaborator or responsible party. Each count is the number of distinct trials containing the mapped drug intervention. This does not establish that the organization manufactures, owns, sells or developed the drug.

Most studied mapped drug conceptsDistinct linked trials per RxNorm concept; one trial may study several drugs.
pembrolizumab184
placebo181
carboplatin90
paclitaxel69
cisplatin65
sitagliptin60
metformin55
raltegravir55
pembrolizumab RxCUI 1547545 · Lead sponsor in 11 linked trial(s) · 19 currently recruiting 184 trials placebo RxCUI 8375 · Lead sponsor in 129 linked trial(s) · 5 currently recruiting 181 trials carboplatin RxCUI 40048 · Lead sponsor in 56 linked trial(s) · 18 currently recruiting 90 trials paclitaxel RxCUI 56946 · Lead sponsor in 50 linked trial(s) · 19 currently recruiting 69 trials cisplatin RxCUI 2555 · Lead sponsor in 49 linked trial(s) · 6 currently recruiting 65 trials sitagliptin RxCUI 593411 · Lead sponsor in 38 linked trial(s) · 0 currently recruiting 60 trials metformin RxCUI 6809 · Lead sponsor in 47 linked trial(s) · 1 currently recruiting 55 trials raltegravir RxCUI 719872 · Lead sponsor in 6 linked trial(s) · 0 currently recruiting 55 trials pemetrexed RxCUI 68446 · Lead sponsor in 30 linked trial(s) · 8 currently recruiting 49 trials lenvatinib RxCUI 1603296 · Lead sponsor in 33 linked trial(s) · 2 currently recruiting 43 trials docetaxel RxCUI 72962 · Lead sponsor in 26 linked trial(s) · 5 currently recruiting 32 trials paclitaxel protein-bound RxCUI 486610 · Lead sponsor in 17 linked trial(s) · 6 currently recruiting 27 trials sitagliptin phosphate RxCUI 621590 · Lead sponsor in 24 linked trial(s) · 0 currently recruiting 26 trials capecitabine RxCUI 194000 · Lead sponsor in 22 linked trial(s) · 6 currently recruiting 25 trials gemcitabine RxCUI 12574 · Lead sponsor in 18 linked trial(s) · 3 currently recruiting 25 trials olaparib RxCUI 1597582 · Lead sponsor in 9 linked trial(s) · 5 currently recruiting 24 trials glimepiride RxCUI 25789 · Lead sponsor in 16 linked trial(s) · 0 currently recruiting 22 trials indinavir sulfate RxCUI 203153 · Lead sponsor in 20 linked trial(s) · 0 currently recruiting 20 trials vorinostat RxCUI 194337 · Lead sponsor in 4 linked trial(s) · 0 currently recruiting 20 trials cyclophosphamide RxCUI 3002 · Lead sponsor in 7 linked trial(s) · 2 currently recruiting 15 trials fluorouracil RxCUI 4492 · Lead sponsor in 14 linked trial(s) · 0 currently recruiting 15 trials oxaliplatin RxCUI 32592 · Lead sponsor in 13 linked trial(s) · 1 currently recruiting 14 trials enzalutamide RxCUI 1307298 · Lead sponsor in 7 linked trial(s) · 4 currently recruiting 13 trials prednisone RxCUI 8640 · Lead sponsor in 10 linked trial(s) · 3 currently recruiting 13 trials

Sponsor roles

lead sponsor818
collaborator755
Advertisement

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.